High circulating levels of soluble CD30 correlate with impaired delayed-type hypersensitivity responses in HIV-infected patients.
Price
P
P
Murray
R J
RJ
John
M
M
French
M A
MA
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000097:blood / Q000276:immunology*; D017730:Ki-1 Antigen / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D017730:Ki-1 Antigen; D018894:Reverse Transcriptase Inhibitors